Amgen Acquires Right To Cytokinetics Heart Drug
Amgen, a biotechnology company, is exercising an option to acquire the rights to an experimental drug 'CK-1827452' from Cytokinetics. The drug, which is currently undergoing mid-stage clinical trial, will be used for the treatment of heart failure.
Cytokinetics will receive $50 million, and is expected to receive up to $600 million in future payments depending on the success of the drug, reported Reuters.
Amgen has paid $75 million to Cytokinetics earlier for the option to the drug and will exercise the option after examining further results of the clinical trial.
Amgen discovers, manufactures, and delivers human therapeutics. The company is focused on the development of medicine for cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.
Related Insight
Suppliers Directory
ASEBIO - Spanish Bioindustry Association
As the Spanish Bioindustry Association, ASEBIO brings together companies, associations, foundations, universities, technology and research centres that undertake their activities either directly or indirectly related to biotechnology in Spain.
Suppliers
Zenatek - Tracking, Monitoring and Reporting Systems for Goods in Transit
Zenatek is a Company with extensive management experience both in the civil and military logistical fields and in the development of software programming, in particular custom and commercial software. Zenatek was founded to supply services in ICT. It plans, realises and runs systems for dealing with and transmitting data and information on “computer” technology.
Suppliers
Helvoet Pharma - Primary and Secondary Packaging Components
Founded in 1970, today Helvoet Pharma is a leading manufacturer of rubber closures and aluminium caps for injectable drugs, medical disposable devices and diagnostic systems.
Suppliers
Johnson Matthey - Scavenging Technologies
For almost 200 years Johnson Matthey has been recycling precious metal. Today, we are experts in recovering metal that is dissolved in solution and in addition we are able to selectively recover other metallic elements and organic compounds.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
CryoEase Microbulk Solutions: a Cost-Effective Alternative to Cylinder Gas Supply
Published by Air Products
White Papers
Cloud Computing—Driving Security, Performance and Quality
Published by Medidata Solutions
White Papers
The Many Faces of Water Vapor
Published by Vaisala
White Papers
Outsourcing Best Practices
Published by Medpace
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.